4,4-diethoxybutanoic acid | 19207-52-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4,4-diethoxybutanoic acid
• 英文别名: 4,4-diethoxy-butyric acid；4,4-Diaethoxy-buttersaeure；4,4-diethoxybutyric acid
• CAS: 19207-52-4
• 化学式: C₈H₁₆O₄
• mdl: MFCD06208343
• 分子量: 176.213
• InChiKey: CSORCORNHIFYTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,4-diethoxybutanoic acid 、 硫酸 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Keimatsu; Sugasawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1926, p. 34

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氰基丙醛二乙基缩醛 在 phosphate buffer 、 immobilized enzyme preparation from Rhodococcus sp 作用下， 反应 24.0h， 以46%的产率得到4,4-diethoxybutanoic acid
  参考文献：
  名称：

  Raadt, Anna de; Klempier, Norbert; Faber, Kurt, Journal of the Chemical Society. Perkin transactions I, 1992, # 1, p. 137 - 140

  摘要：

  DOI：

文献信息

• Acylbenzoxazines for enhancing synaptic response
  申请人：The Regents of the University of California

  公开号：US06124278A1

  公开（公告）日：2000-09-26

  Compounds based on the benzoxazine ring system that are remarkably more potent than corresponding benzoyl piperidines for enhancing synaptic responses mediated by AMPA receptors are disclosed, as are methods for the preparation thereof, and methods for their use for treatment of subjects suffering from impaired nervous or intellectual functioning due to deficiencies in the number of excitatory synapses or in the number of AMPA receptors. The invention compounds can also be used for the treatment of non-impaired subjects for enhancing performance in sensory-motor and cognitive tasks which depend on brain networks utilizing AMPA receptors and for improving memory encoding.

  基于苯并噁嗪环系统的化合物比对应的苯甲酰哌啶在增强由AMPA受体介导的突触反应方面更加有效，公开了这些化合物的制备方法以及它们用于治疗因兴奋性突触数量不足或AMPA受体数量不足而导致神经或智力功能受损的受试者的方法。这些发明化合物还可用于治疗非受损受试者，以增强依赖利用AMPA受体的大脑网络执行感觉运动和认知任务的表现，并提高记忆编码。
• ERG TARGETED THERAPY
  申请人：The Regents of the University of Michigan

  公开号：US20180273595A1

  公开（公告）日：2018-09-27

  The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.

  本公开涉及癌症治疗的组合物和方法，包括但不限于针对癌症标志物的靶向抑制。特别是，本公开涉及将复发性基因融合作为癌症的临床靶点。
• 8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY
  申请人：Xiamen Sinopeg Biotech Co., Ltd.

  公开号：EP3315531A1

  公开（公告）日：2018-05-02

  Disclosed are an 8-arm polyethylene glycol (PEG) derivative (formula 1), manufacturing method and modified bio-related substance thereby, wherein a tetravalent group U and four trivalent groups Ec form a highly symmetric octavalent central structure CORE0 together, Lc connects the octavalent center to eight PEG arms having polydiversity or monodiversity and having n1-n8 as the degrees of polymerization thereof. The terminal of one PEG chain is connected to at least one functional group F (k ≥ 1), and said PEG chain and F can be directly connected (g = 0) or connected with a divalent linking group L0 connected with a terminal branched group G (g = 1) therebetween. The latter provides more reacting sites to combine more pharmaceutical molecules, thereby increasing the drug loading capacity. The near-center symmetric structure of the derivative allows more precise control over the molecular weight during large-scale production, thereby facilitating acquisition of a product having a narrower molecular weight distribution. A bio-related substance modified thereby has a more uniform and controllable performance.

  本发明公开了一种 8 臂聚乙二醇（PEG）衍生物（式 1）、其制造方法和改性生物相关物质，其中一个四价基团 U 和四个三价基团 Ec 共同形成一个高度对称的八价中心结构 CORE0，Lc 将八价中心连接到八个 PEG 臂上，这些 PEG 臂具有多元性或单元性，其聚合度为 n1-n8。一条 PEG 链的末端与至少一个官能团 F（k ≥ 1）相连，所述 PEG 链和 F 可以直接相连（g = 0），也可以通过二价连接基 L0 与中间的末端支化基 G（g = 1）相连。后者提供了更多的反应位点，可以结合更多的药物分子，从而提高药物负载能力。衍生物的近中心对称结构可以在大规模生产过程中更精确地控制分子量，从而有利于获得分子量分布更窄的产品。由此改性的生物相关物质具有更均匀、更可控的性能。
• Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof
  申请人：XIAMEN SINOPEG BIOTECH CO., LTD.

  公开号：US10434182B2

  公开（公告）日：2019-10-08

  Disclosed are an eight-arm polyethylene glycol (PEG) derivative (formula I), production method therefor and modified bio-related substance thereby. Wherein, one tetravalent group U together with four trivalent groups Ec form a highly symmetrical octavalent group CORE0; Lc connects the octavalent group to eight PEG chains having polydispersity or monodispersity and having n1 to n8 as the degree of polymerization thereof; the terminal of one PEG chain is connected to at least one functional group F (k≥1); said PEG chain and F therebetween can be directly connected (g=0) or be indirectly connected via a linking group L0 to a terminal end-branching group G (g=1); the latter provides more reactive sites for binding more drug molecules and increases the drug loading. The eight-arm polyethylene glycol derivative has a centrosymmetric or approximately centrosymmetric structure, and leads to more precise control of the molecular weight in large-scale production and much narrower distribution of molecular weight for products. The modified bio-related substance thereby has a more uniform and controllable performance.

  本发明公开了一种八臂聚乙二醇（PEG）衍生物（式 I）、其生产方法及其改性生物相关物质。其中，一个四价基团 U 与四个三价基团 Ec 形成一个高度对称的八价基团 CORE0；Lc 将八价基团连接到八条具有多分散性或单分散性且聚合度为 n1 至 n8 的 PEG 链上；一条 PEG 链的末端与至少一个官能团 F 连接（k≥1）；所述 PEG 链和 F 之间可以直接连接（g=0），也可以通过连接基团 L0 与末端支化基团 G 间接连接（g=1）；后者提供了更多的反应位点，可以结合更多的药物分子，增加药物负载量。八臂聚乙二醇衍生物具有中心对称或近似中心对称结构，因此在大规模生产中可以更精确地控制分子量，产品的分子量分布也更窄。因此，改性生物相关物质的性能更均匀、更可控。
• ERG targeted therapy
  申请人：The Regents of the University of Michigan

  公开号：US10774122B2

  公开（公告）日：2020-09-15

  The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.

  本公开涉及用于癌症治疗的组合物和方法，包括但不限于靶向抑制癌症标志物。特别是，本公开涉及作为癌症临床靶点的复发性基因融合。